Actually, there are several phase II and phase III studies ongoing about the use of FXI inhibitors in cancer patients to prevent or treat venous thromboembolic events, to prevent catheter-related thrombosis, and to prevent arterial thromboembolic events, summarized in Table 2. The gene discussed is F11; the disease is cancer.